RKIPEGFR:

Diana Cardoso-Carneiro1,2, Joana Pinheiro1,2, Patrícia Fontão1,2

  • 1Life and Health Sciences Research Institute (ICVS), Health Sciences School, University of Minho, 4710-057 Braga, Portugal.

Cancers
|June 27, 2024
PubMed
概括

拉夫激酶抑制蛋白 (RKIP) 作为一种瘤抑制剂. 它的损失与预后不佳相关,在许多固体瘤中与EGFR相反相关,特别是宫癌,影响癌症的进展.